Veracyte Obtains Medicare Coverage for Prosigna Breast Cancer Test
Veracyte, Inc. (VCYT) has obtained Medicare coverage through MolDX for its Prosigna Breast Risk of Recurrence test. The reimbursement decision took effect on August 19, 2026, and applies to postmenopausal patients with early-stage, estrogen receptor-positive breast cancer with zero to three affected nodes.
The coverage decision follows the initial U.S. launch of the diagnostic test in June 2026. Establishing Medicare reimbursement provides medical providers and patients with direct coverage for the test, which helps physicians evaluate whether chemotherapy can be safely avoided. Shares of Veracyte rose 2.02% to $44.39 following the announcement.
Investors will look for signs of increased physician adoption and volume growth in upcoming financial disclosures. Further expansion of commercial insurance coverage among private healthcare plans will also be a key factor in tracking the overall U.S. market adoption for the Prosigna test.
Key points
- Veracyte secured MolDX Medicare coverage for its Prosigna Breast Risk of Recurrence diagnostic test.
- The reimbursement decision went into effect on August 19, 2026, following the U.S. product launch in June 2026.
- Coverage applies to postmenopausal patients with early-stage, ER-positive breast cancer with 0-3 positive nodes.
- The diagnostic test helps physicians and patients make chemotherapy-sparing treatment choices.
- Veracyte shares traded up 2.02% at $44.39 following the coverage update.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is Veracyte's Prosigna test covered for by Medicare?
Medicare covers the Prosigna test for postmenopausal patients with early-stage, ER-positive breast cancer and zero to three affected nodes to help guide chemotherapy decisions.
When did Medicare coverage for Veracyte's Prosigna test take effect?
The MolDX Medicare coverage for the Prosigna test became effective on August 19, 2026, after the U.S. market launch in June 2026.
How did Veracyte stock react to the Medicare coverage news?
Veracyte shares rose 2.02% to $44.39 following the report.